Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 1:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hayfever Clear all
Completed Phase 4 Interventional Results available

Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine

NCT00502775
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
fluticasone furoate, fexofenadine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
42
States / cities
Little Rock, Arkansas • Albany, Georgia • Columbus, Georgia + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Sep 25, 2026, 1:32 PM EDT
Completed Not applicable Interventional Results available

Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?

NCT00618332
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
mometasone furoate nasal spray, placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 25, 2026, 1:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Intranasal Steroids and the Nasal Ocular Response

NCT00473915
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
fluticasone furoate
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 2, 2013 · Synced Sep 25, 2026, 1:32 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months

NCT00628108
View directory record Official record
Conditions
Allergic Rhinitis, Chronic Urticaria
Interventions
Levocetirizine 1.25 mg, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
6 Months to 11 Months
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 25, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis

NCT01578278
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Bepotastine besilate formulation, Fluticasone propionate, Bepotastine besilate-fluticasone propionate, Placebo Comparator
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
12 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 25, 2026, 1:32 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00651118
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo, azelastine Hcl, azelastineHcl / fluticasone propionate, fluticasone propionate
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
832 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
43
States / cities
Scottsdale, Arizona • Encinitas, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Sep 25, 2026, 1:32 PM EDT
Completed Phase 1 Interventional

Clinical Trial of STAHIST in Seasonal Allergic Rhinitis Patients

NCT00932256
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
STAHIST NDC #58407-536-01
Drug
Lead sponsor
Magna Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 7, 2010 · Synced Sep 25, 2026, 1:32 PM EDT
Completed No phase listed Observational

Examining the Link Between Depression and Seasonal Allergies

NCT00770068
View directory record Official record
Conditions
Depression
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Sep 25, 2026, 1:32 PM EDT
Completed Phase 4 Interventional Results available

Study Of Allergic Rhinitis In Patients Who Also Have Asthma

NCT00296491
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol (FSC), montelukast (MON), fluticasone propionate (FP), placebo nasal, ADVAIR DISKUS, placebo capsule, placebo DISKUS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years and older
Enrollment
725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
104
States / cities
Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 25, 2026, 1:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults

NCT03814720
View directory record Official record
Conditions
Influenza Infection
Interventions
VRC-FLUNPF099-00-VP (H1ssF_3928)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 25, 2026, 1:32 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR

NCT00574379
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Hay Fever, Allergic Conjunctivitis, Hypersensitivity
Interventions
Bilastine, Placebo
Drug
Lead sponsor
Faes Farma, S.A.
Industry
Eligibility
12 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Oklahoma City, Oklahoma • Austin, Texas • Kerrville, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 25, 2026, 1:32 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Pilot Study to Evaluate Ear Acupressure Effects in Treating Seasonal Allergic Rhinitis

NCT01921348
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
acupressure pellets
Device
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Sep 25, 2026, 1:32 PM EDT
Completed Phase 3 Interventional

A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)

NCT01673659
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Mometasone furoate, Nasonex Nasal Spray, Placebo nasal spray
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Sep 25, 2026, 1:32 PM EDT
Completed Phase 1 Interventional

A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL

NCT03931993
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo comparator, Grass MATA MPL
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
Edison, New Jersey • Ocean City, New Jersey • Springfield, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 25, 2026, 1:32 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00740792
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
azelastine HCl/fluticasone propionate, azelastine Hcl, fluticasone propionate, placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
39
States / cities
Scottsdale, Arizona • Encinitas, California • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Sep 25, 2026, 1:32 PM EDT
Completed Phase 3 Interventional

A Study Comparing the Bioequivalence of Triamcinolone Acetonide Aqueous Nasal Spray (Apotex, Inc.) to That of Nasacort® AQ Nasal Spray (Sanofi-Aventis Pharmaceutical Products, Inc.) In the Treatment of Seasonal Allergic Rhinitis

NCT00987233
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
triamcinolone acetonide aqueous nasal spray (Apotex Inc.), triamcinolone acetonide aqueous nasal spray (Nasacort® AQ), Placebo
Drug
Lead sponsor
Apotex Inc.
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 29, 2009 · Synced Sep 25, 2026, 1:32 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen

NCT05540717
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Rhinoconjunctivitis
Interventions
PQ Grass, Placebo
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
33
States / cities
Centennial, Colorado • Denver, Colorado • Lexington, Kentucky + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 25, 2026, 1:32 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT01279057
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals), Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray, Placebo
Drug
Lead sponsor
Sandoz
Industry
Eligibility
12 Years and older
Enrollment
727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 25, 2026, 1:32 PM EDT
Completed Phase 3 Interventional

Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)

NCT00261287
View directory record Official record
Conditions
Hay Fever, Perennial Allergic Rhinitis
Interventions
Ciclesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
2 Years to 5 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Long Beach, California • Normal, Illinois • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Sep 25, 2026, 1:32 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies

NCT00720278
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
0.15% azelastine hydrochloride 1644 mcg daily, 0.1% azelastine hydrochloride 1096 mcg daily, Placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
29
States / cities
Oxford, Alabama • Encinitas, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 25, 2026, 1:32 PM EDT
Completed Phase 1 Interventional

A Study To Explore The Effect On Inflammatory Markers After Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis And The Effect Of A Single Dose Of Ibuprofen Or Fluticasone Propionate On The Allergen Response.

NCT01064726
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Ibuprofen, Fluticasone propionate, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
19 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 1, 2010 · Synced Sep 25, 2026, 1:32 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)

NCT02870205
View directory record Official record
Conditions
Seasonal Allergic Rhinitis (SAR)
Interventions
GSP 301 NS, GOM-NS, GMM-2 NS, GSP 301 placebo NS
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
12 Years and older
Enrollment
1,176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
43
States / cities
Mission Viejo, California • Orange, California • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Sep 25, 2026, 1:32 PM EDT
Completed Phase 3 Interventional

A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy

NCT06602739
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
REGN5713, REGN5715, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 25, 2026, 1:32 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of rEV131 in Allergic Rhinitis

NCT00247520
View directory record Official record
Conditions
Hay Fever
Interventions
topical nasal rEV131
Drug
Lead sponsor
Evolutec Group
Industry
Eligibility
18 Years to 80 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2005 · Synced Sep 25, 2026, 1:32 PM EDT